This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Comment: Thermo Fisher-Qiagen deal may face additional scrutiny in Covid-19 days

By Natalie McNelis ( April 30, 2020, 16:26 GMT | Comment) -- Thermo Fisher’s acquisition of German-Dutch genetic testing company Qiagen could encounter resistance from investment-screening watchdogs in EU countries, as well as the usual merger-control hurdles, due to the company’s role in the fight against Covid-19. Thermo Fisher has said it has “voluntarily” submitted the deal for investment screening in Germany, and intends to do so in France and Spain.Thermo Fisher’s acquisition of German-Dutch genetic testing company Qiagen could encounter resistance from investment-screening watchdogs in EU countries, as well as the usual merger-control hurdles, due to the company’s role in the fight against Covid-19....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login